DHL is enhancing high-quality logistics operations across the Americas, Asia-Pacific, and EMEA to meet evolving needs of life sciences and healthcare industry. Supporting advanced therapies and next gen treatments with state-of-the-art cooling transport and storage capabilities.
CT Bureau
DHL Group has announced a strategic investment of £2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector. This investment supports the Group’s Strategy 2030 and reinforces DHL’s commitment to helping healthcare customers grow, innovate, and serve patients more effectively worldwide. With 50 per cent of the investment allocated to the Americas, 25 per cent to Asia-Pacific, and 25 per cent to the EMEA region, DHL is expanding its footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.
The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints—from storage, order fulfilment, and distribution to global shipping and last-mile delivery—creating resilient, scalable, and responsive supply chains. A significant part of the investment will be allocated to establish new cross-divisional GPD-certified Pharma Hubs for multi-temperature shipments lanes, expand cold chain capacity in existing facilities, new temperature-controlled vehicles, and passive and active packaging solutions to ensure sustainable delivery.
As the demand grows in clinical trials, biopharma, and cell and gene therapies, DHL is also investing in high-quality, specialised cooling infrastructure to accommodate low and ultra-low temperature ranges. Additionally, the group will implement cutting-edge IT systems that provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.
With its new sector brand, DHL Health Logistics, the group consolidates its life sciences and healthcare expertise under one unified umbrella. This creates a seamless, end-to-end experience for customers, simplifying the management of complex, cross-border supply chains with confidence, agility and high-quality service. The approach has been designed to meet the needs of pharmaceutical, biopharma, and medical customers who require agile and connected logistics solutions that go beyond traditional service lines.
“Like the DHL Group’s purpose of ‘connecting people, improving lives’, our strategic investment in life sciences and healthcare is driven by delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO, DHL Supply Chain.
“We are building high-quality, integrated logistics solutions that are as innovative and reliable
as the products our customers create, thereby ensuring that patients everywhere receive the correct treatment at the right time.” Through this strategic investment, the DHL Group is reinforcing its commitment to the life science and healthcare sector and demonstrating a
profound dedication to patient care by ensuring the efficient and reliable delivery of essential pharmaceutical products, clinical trials and cell and gene
therapies. This approach positions DHL Group at the forefront of the industry, equipped to tackle challenges and seize opportunities in a rapidly transforming market.
